INOCRAS

ActiveBorn in South Korea, based elsewhere

Whole-genome cancer diagnostics

Healthtech›whole-genome cancer diagnostics

HQKorean origin; HQ San Diego (US)

Last roundSeries B · Aug 2026

Country of originSouth KoreaBorn here, based elsewhere

BasedKorean origin; HQ San Diego (US)

Born in South Korea, based elsewhere

INOCRAS is listed by the South Korea ranking as a company founded by South Korea-linked founders but headquartered abroad: it is not ranked in South Korea. Korean origin; HQ San Diego (US).

Funding history

Date	Round	Amount	Type	Investors	Source
Aug 2026	Series B	USD ~31M (KRW 44.35bn)	—	IMM Investment	en.sedaily.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
South Korea · all sectors	Born here, based elsewhere	—	Edition 0 – beta · October 2026	18 Oct 2026

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of INOCRAS as a PDF, on one of three angles only:

ValuationWhat is INOCRAS worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

INOCRAS is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in South Korean startups Declare an interest in South Korean healthtech Name INOCRAS as a preferred company (measures demand, promises nothing)

South Korea poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run INOCRAS?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements1 source

Read by the AI at the next edition.

Comparable companies in South Korea

Full South Korea ranking →

Promedius#35Healthtech › AI osteoporosis screeningTens of M$Toss#1Fintech › financial super-appDecacorn Yanolja#2Travel › travel super-app and hospitality cloudUnicorn Musinsa#3Commerce › fashion e-commerce and retailUnicorn

Investors in INOCRAS: IMM Investment

Sources. en.sedaily.com

Last updated: Oct 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.